{"id":"cf316508-c198-50ca-99bd-d2bfc8ad6247","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-15r-pgd2-blocks-platelets","predicate":"inhibits","statement":"Aspirin increased 15R-prostaglandin D2 but not 15R-prostaglandin E2 in isolated human leukocytes activated with lipopolysaccharide to induce cyclooxygenase-2, and 15R-prostaglandin D2 inhibited human platelet aggregation induced by the thromboxane receptor agonist U46,619, an effect abrogated by an antagonist of the DP1 prostanoid receptor, so 15R-prostaglandins are novel products of aspirin therapy that may contribute to its antiplatelet and other effects.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"3687548d-8097-5bbc-9afc-cdd6d6663c63","mechanism_event_label":"One of those mirror-image products is itself an antiplatelet agent, working through a different receptor.","subject":{"id":"f2e59c5a-a474-5a80-b704-fc02f4b919ac","slug":"15r-pgd2","display_name":"15R-prostaglandin D2","entity_type_key":"small_molecule"},"object":{"id":"a65aa8a9-a3a0-524d-904a-28bc1c42bd05","slug":"platelet-aggregation-asa","display_name":"Cyclooxygenase-dependent platelet aggregation","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"3687548d-8097-5bbc-9afc-cdd6d6663c63","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-15r-pgd2-blocks-platelets-event","event_type":"biochemical_relationship","label":"One of those mirror-image products is itself an antiplatelet agent, working through a different receptor.","description":"Aspirin increased 15R-prostaglandin D2 but not 15R-prostaglandin E2 in isolated human leukocytes activated with lipopolysaccharide to induce cyclooxygenase-2, and 15R-prostaglandin D2 inhibited human platelet aggregation induced by the thromboxane receptor agonist U46,619, an effect abrogated by an antagonist of the DP1 prostanoid receptor, so 15R-prostaglandins are novel products of aspirin therapy that may contribute to its antiplatelet and other effects.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"687b5c92-c9e6-5d8f-b517-1d5f2903567d","slug":"ptgdr","display_name":"Human prostaglandin D2 receptor 1 / PTGDR","entity_type_key":"protein"},"role":"mediating_receptor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"cda05399-1c07-5459-b8e2-0edcf5066e94","slug":"acetylated-cox2","display_name":"Aspirin-acetylated cyclooxygenase-2","entity_type_key":"protein_state"},"role":"producing_enzyme","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2e59c5a-a474-5a80-b704-fc02f4b919ac","slug":"15r-pgd2","display_name":"15R-prostaglandin D2","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"a65aa8a9-a3a0-524d-904a-28bc1c42bd05","slug":"platelet-aggregation-asa","display_name":"Cyclooxygenase-dependent platelet aggregation","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/aspirin-research/30096040.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\", \"start_char\": 0, \"end_char\": 1666, \"text_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Aspirin acetylation, with lipopolysaccharide-induced cyclooxygenase-2 in leukocytes and a thromboxane receptor agonist on platelets","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Shows the acetylated enzyme keeps more of its original chemistry than the HETE story implies, and links the product to a measured platelet effect. Isolated cells rather than treated people.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"One of those mirror-image products is itself an antiplatelet agent, working through a different receptor.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Recombinant enzyme and isolated leukocytes and platelets","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7aca55b4-dad4-5fbf-8264-84dc5a61a292","evidence_kind":"source_excerpt","locator":"Lines 299-310","start_line":299,"end_line":310,"excerpt":"### asa-15r-pgd2-blocks-platelets\nAspirin increased 15R-prostaglandin D2 but not 15R-prostaglandin E2 in isolated human leukocytes activated with lipopolysaccharide to induce cyclooxygenase-2, and 15R-prostaglandin D2 inhibited human platelet aggregation induced by the thromboxane receptor agonist U46,619, an effect abrogated by an antagonist of the DP1 prostanoid receptor, so 15R-prostaglandins are novel products of aspirin therapy that may contribute to its antiplatelet and other effects.\nCondition category: normal\nnutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.\nplain_language: One of those mirror-image products is itself an antiplatelet agent, working through a different receptor.\norganism: Human\ntissue_or_cell_type: Recombinant enzyme and isolated leukocytes and platelets\nexperimental_model: Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays\nlimitations: Shows the acetylated enzyme keeps more of its original chemistry than the HETE story implies, and links the product to a measured platelet effect. Isolated cells rather than treated people.\nexposure: Aspirin acetylation, with lipopolysaccharide-induced cyclooxygenase-2 in leukocytes and a thromboxane receptor agonist on platelets\nevidence_span: {\"source_cache\": \"artifacts/aspirin-research/30096040.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\", \"start_char\": 0, \"end_char\": 1666, \"text_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\"}\n[asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","model_system":"Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"712cf519-cd27-5a8b-9e2f-961a98d7a27e","stable_key":"import-f8641d02-8413-5bd8-92e9-62ad49286e81","title":"Aspirin: the serine it acetylates, the enzyme that acetylation creates, the dose that separates platelet from vessel wall, and the metabolite that is a different drug (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"93dd4343051c131e40d4fc3c95a978cd65478c13dcdb3f2d42507c49b09cb647","revision_id":"694e8ee7-49ca-5e6c-b58b-8ba8f82c2ad8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}